Suggestions
Paul Y. Song, MD
Chief Executive Officer at NKGen Biotech, Inc.
Paul Y. Song, MD
Paul Y. Song, MD is the Chief Executive Officer and Chairman at NKGen Biotech, Inc. He has over 30 years of experience in the biotechnology and medical industry, with a focus on oncology, immunology, and therapeutic development.1
Key Positions
- Chief Executive Officer and Chairman, NKGen Biotech, Inc. (January 2023 - Present)1
- Vice Chairman of the Board, NKGen Biotech, Inc. (December 2021 - Present)1
- Co-Founder & CEO, Fuse Biotherapeutics (July 2021 - January 2023)1
- Chief Medical Advisor, Hawkeye Bio, Inc. (July 2017 - Present)1
Education and Training
- BA with honors, Biological Sciences, University of Chicago (1983 - 1987)1
- MD, The George Washington University School of Medicine and Health Sciences (1987 - 1991)1
- Chief Resident '95, Radiation and Cellular Oncology, The University of Chicago Pritzker School of Medicine (1992 - 1995)1
- ASTRO Research Fellow - Dept. of Radiation and Cellular Oncology, The University of Chicago Pritzker School of Medicine (1995 - 1996)1
Expertise
- Board Certified Radiation Oncologist1
- Skilled in Management, Translational Medicine, Clinical Trials, Regulatory Affairs, Medical Devices, Diagnostics, Governmental Affairs, and Healthcare Policy1
Dr. Song is a prominent figure in the biotech industry and has been actively involved in the fight against COVID-19, advocating for mask-wearing and raising awareness about the seriousness of the virus.2 His LinkedIn username is paul-y-song-md-7664147.1
Highlights
As more data emerges on how high levels of α-synuclein in Alzheimer’s disease are correlated with disease progression and worsened cognitive function, we are pleased to present our data showing SNK01’s ability to reduce α-synuclein and improve cognitive function.
Proud to present our latest data at #AAIC24 showing that our enhanced SNK01 natural killer cells are very safe and can cross the blood brain barrier to reduce α-synuclein proteins and improve cognitive function in Alzheimer’s patients. Emerging evidence suggests that α-synuclein is associated with a worse clinical presentation and no current therapeutic for Alzheimer’s addresses this. While we have previously shown that SNK01 can improve CSF levels of amyloid and tau proteins as well as reduce neuroinflammation caused by auto-reactive T cells, being able to show real in-human activity against α-synuclein provides yet another potential way SNK01 can work against not only Alzheimer’s, but also in Parkinson’s and Lewy Body Dementia which are primarily attributed to α-synucleinapathy. #aaic24 #alzheimers #αsynuclein #parkinsons #lewybodydementia #neuroinflammation #nkcells #nkgenbiotech #snk01
